Gadolinium: clinical trials recruiting now
3
Recruiting trials
6
Conditions studied
2
US states with sites
2
Countries
FDA drug label
- FDA-approved
- Yes. Gadolinium appears in the FDA drug-label database. Marketed as Gadolinium Metallicum.
Phase breakdown
Phase 1 2
Phase 2 1
Conditions being studied
| Condition | Trials |
|---|---|
| Brain Metastases | 1 |
| Epilepsy | 1 |
| Hypertension | 1 |
| Hypertrophy | 1 |
| Lung cancer | 1 |
| Nonsmall Cell Lung Cancer Stage III | 1 |
Recruiting trials involving Gadolinium
- Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
- Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection
- Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
Common questions
Is Gadolinium FDA-approved?
Yes, marketed as Gadolinium Metallicum.
How many recruiting trials involve Gadolinium?
3 recruiting trials across 6 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.